Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 18, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 500,000 ordinary shares.
- Purchase Price: 1,414.42 pence per share.
- Treasury Shares Held: 242,482,678 shares (post-transaction).
- Shares in Issue: 5,752,024,409 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. The company acquired 500,000 shares on January 18, 2007, which are now held in Treasury. Consequently, the total number of shares in issue (representing total voting rights) remains 5,752,024,409, while the Treasury holding increased to 242,482,678.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,752,024,409) for calculating ownership percentages under Financial Services Authority Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (242,482,678) for accurate fully diluted share count calculations.
- Note that this filing is a regulatory disclosure of a share buyback and does not contain financial performance data for the period.